JP2003527430A - １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤 - Google Patents

１５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤

Info

Publication number
JP2003527430A
JP2003527430A JP2001568431A JP2001568431A JP2003527430A JP 2003527430 A JP2003527430 A JP 2003527430A JP 2001568431 A JP2001568431 A JP 2001568431A JP 2001568431 A JP2001568431 A JP 2001568431A JP 2003527430 A JP2003527430 A JP 2003527430A
Authority
JP
Japan
Prior art keywords
keto
prostaglandin compound
compound
prostaglandin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001568431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003527430A5 (enExample
Inventor
隆司 上野
行彦 真島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of JP2003527430A publication Critical patent/JP2003527430A/ja
Publication of JP2003527430A5 publication Critical patent/JP2003527430A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001568431A 2000-03-24 2001-03-23 １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤 Pending JP2003527430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19175500P 2000-03-24 2000-03-24
US60/191,755 2000-03-24
PCT/JP2001/002307 WO2001070233A2 (en) 2000-03-24 2001-03-23 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof

Publications (2)

Publication Number Publication Date
JP2003527430A true JP2003527430A (ja) 2003-09-16
JP2003527430A5 JP2003527430A5 (enExample) 2007-12-27

Family

ID=22706808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001568431A Pending JP2003527430A (ja) 2000-03-24 2001-03-23 １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤

Country Status (13)

Country Link
US (1) US7129272B2 (enExample)
EP (1) EP1267882B1 (enExample)
JP (1) JP2003527430A (enExample)
KR (1) KR100788226B1 (enExample)
CN (1) CN1443070A (enExample)
AR (1) AR030275A1 (enExample)
AT (1) ATE428429T1 (enExample)
AU (2) AU2001239551B8 (enExample)
CA (1) CA2403086C (enExample)
DE (1) DE60138371D1 (enExample)
NZ (1) NZ521464A (enExample)
TW (1) TWI284535B (enExample)
WO (1) WO2001070233A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106915A1 (ja) * 2005-03-31 2006-10-12 Asahi Glass Company, Limited プロスタグランジンＦ2α誘導体を有効成分として含む網膜神経細胞保護剤
JP2008528440A (ja) * 2005-01-27 2008-07-31 スキャンポ・アーゲー 中枢神経系障害の処置のための方法および組成物
US8252945B2 (en) 2005-04-13 2012-08-28 Ube Industries, Ltd. Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002006A (es) 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
CN1605336A (zh) 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
EP1803809A3 (en) * 2005-08-12 2007-12-19 Abgenomics Corporation Modulation of peroxisome proliferator-activated receptors
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
CN102143753B (zh) * 2008-09-04 2013-07-03 参天制药株式会社 含有15,15-二氟前列腺素F2α衍生物作为有效成分的毛发生长促进剂
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02108A (ja) * 1987-09-18 1990-01-05 Ueno Seiyaku Oyo Kenkyusho:Kk 眼圧降下剤
JPH03251535A (ja) * 1989-11-22 1991-11-11 Ueno Seiyaku Oyo Kenkyusho:Kk 脳機能改善処置剤
JPH08277222A (ja) * 1995-04-05 1996-10-22 Green Cross Corp:The 神経疾患の予防治療剤
JPH0987179A (ja) * 1995-03-10 1997-03-31 R Tec Ueno:Kk 視神経障害改善剤
JPH11222436A (ja) * 1997-10-21 1999-08-17 Japan Science & Technology Corp アポトーシス抑制剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6087395A (en) 1997-10-21 2000-07-11 Japan Science And Technology Corporation Isocarbacyclin derivatives as apoptosis inhibitors
JP2000169394A (ja) * 1998-12-04 2000-06-20 Yoshitomi Pharmaceut Ind Ltd アポトーシス誘導剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02108A (ja) * 1987-09-18 1990-01-05 Ueno Seiyaku Oyo Kenkyusho:Kk 眼圧降下剤
JPH03251535A (ja) * 1989-11-22 1991-11-11 Ueno Seiyaku Oyo Kenkyusho:Kk 脳機能改善処置剤
JPH0987179A (ja) * 1995-03-10 1997-03-31 R Tec Ueno:Kk 視神経障害改善剤
JPH08277222A (ja) * 1995-04-05 1996-10-22 Green Cross Corp:The 神経疾患の予防治療剤
JPH11222436A (ja) * 1997-10-21 1999-08-17 Japan Science & Technology Corp アポトーシス抑制剤

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528440A (ja) * 2005-01-27 2008-07-31 スキャンポ・アーゲー 中枢神経系障害の処置のための方法および組成物
WO2006106915A1 (ja) * 2005-03-31 2006-10-12 Asahi Glass Company, Limited プロスタグランジンＦ2α誘導体を有効成分として含む網膜神経細胞保護剤
US9138438B2 (en) 2005-03-31 2015-09-22 Asahi Glass Company, Limited Method for protecting a retinal neuronal cell
US8252945B2 (en) 2005-04-13 2012-08-28 Ube Industries, Ltd. Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient

Also Published As

Publication number Publication date
CA2403086A1 (en) 2001-09-27
AU3955101A (en) 2001-10-03
WO2001070233A3 (en) 2002-06-13
WO2001070233A2 (en) 2001-09-27
EP1267882B1 (en) 2009-04-15
TWI284535B (en) 2007-08-01
US20020025985A1 (en) 2002-02-28
KR20020081474A (ko) 2002-10-26
KR100788226B1 (ko) 2007-12-26
DE60138371D1 (de) 2009-05-28
AR030275A1 (es) 2003-08-20
CA2403086C (en) 2010-08-17
US7129272B2 (en) 2006-10-31
EP1267882A2 (en) 2003-01-02
AU2001239551B2 (en) 2005-07-21
ATE428429T1 (de) 2009-05-15
NZ521464A (en) 2004-09-24
CN1443070A (zh) 2003-09-17
AU2001239551B8 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
JP5073588B2 (ja) １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
JP3217293B2 (ja) 発毛・育毛剤
JP5686819B2 (ja) 黄斑浮腫を処置するための医薬組成物
JP2012031202A (ja) 腹部不快感の処置のためのプロスタグランジン誘導体
JPH0570354A (ja) 創傷治癒促進剤
JP2003527430A (ja) １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤
JP4705782B2 (ja) 肥満の処置のためのプロスタグランジン化合物
JP5222462B2 (ja) 眼科用組成物
AU2001239551A1 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
AU2010237744B2 (en) Method and composition for treating macular degeneration
JP2004529177A (ja) 高眼圧症および緑内障の処置方法
JP4091132B2 (ja) 門脈圧亢進抑制剤
US20030060511A1 (en) Method for treatment of ocular hypertension and glaucoma
WO2003011178A2 (en) Method for treatment of ocular hypertension and glaucoma
JP2609479B2 (ja) カリウム排泄剤
JP3023059B2 (ja) 脳機能改善処置剤
JP2005519978A (ja) 高眼圧症および緑内障の処置方法
AU2002255346A1 (en) Method for treatingocular hypertension and glaucoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110715

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111220